GlassScriptPhysician profile
David A Marcantel
NPI 1275530628
$1,862.33
in general payments reported to CMS, 2019-2025
28 companies · $458 in 2025
The $458 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $90.69 · 2021: $57.69 · 2022: $282 · 2023: $220 · 2024: $338 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $46.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.87 |
| Education | $46.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $234.99 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $224.17 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Thinprep 2000 Processor |
| Abbvie INC. | $182.93 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $119.10 | 2022-2025 | |
| Pfizer INC. | $106.78 | 2023-2025 | |
| Optumhealth Care Solutions, LLC | $103.33 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Sumitomo Pharma America, INC. | $91.80 | 2023-2025 | Myfembree |
| Allergan, INC. | $89.24 | 2019 | |
| Duchesnay USA Incorporated | $70.49 | 2019 | |
| Biogen, INC. | $68.45 | 2024-2025 | Zurzuvae |
| Meditrina | $58.48 | 2021-2023 | |
| Exeltis, USA INC. | $58.23 | 2019-2023 | Slynd |
| Myovant Sciences INC. | $53.76 | 2022 | |
| Millicent US INC | $53.40 | 2020-2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $46.29 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $45.80 | 2019-2020 | |
| Amgen INC. | $39.70 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $33.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $32.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.37 | 2025 | |
| Sage Therapeutics, LLC | $23.75 | 2023 | |
| Coopersurgical, INC. | $19.30 | 2025 | Paragard T 380a |
| Vertical Pharmaceuticals, LLC | $18.48 | 2019 | |
| Organon LLC | $17.96 | 2022 | |
| Karl Storz Endoscopy-America | $16.51 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.65 | 2020 | |
| Daiichi Sankyo INC. | $11.41 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marcantel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.